Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling

Adding daratumumab to VTd improves post-transplant response and MRD negativity in real-world practice. The magnitude of benefit diminishes with increasing numbers of high-risk cytogenetic abnormalities, supporting the value of risk-adapted strategies and real-world MRD assessment in treatment evaluation.

Authors

Institutions

Publication Details

Journal
Clinical Lymphoma Myeloma & Leukemia
Published
2025-11-11
DOI
https://doi.org/10.1016/j.clml.2025.11.003
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling

Sigurður Y. Kristinsson, Leonora Conneely, James Croft, Katy Smith et al.
Clinical Lymphoma Myeloma & Leukemia
Multiple Myeloma Research and Treatments
article

Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling

Sigurður Y. Kristinsson, Leonora Conneely, James Croft, Katy Smith, Kevin Boyd, Pawel Kaczmarek, Francesca Gay, Edward Renaudon‐Smith, Chin Fen Neoh, Giuseppe Bertuglia, Christina Messiou, Stefania Bonetto, Guy Pratt, Dingle Spence, Alan Dunlop, Elisa Seneca, Charlotte Pawlyn, Martin Kaiser, Jindriska Lindsay, Emma Nicholson, Tracy Thornton, Graham Jackson, Mikel Valganon Petrizan, Lillian M. Fuller, Lauren Ellis, TOMMY J. BROWN, Timothy Corbett, Mark Ethell, Lewis Vanhinsbergh
article en

Abstract

Adding daratumumab to VTd improves post-transplant response and MRD negativity in real-world practice. The magnitude of benefit diminishes with increasing numbers of high-risk cytogenetic abnormalities, supporting the value of risk-adapted strategies and real-world MRD assessment in treatment evaluation.

Clinical Lymphoma Myeloma & LeukemiaVol. 26(2)
University Hospitals Birmingham NHS Foundation Trust (GB), Institute of Cancer Research (GB), Frimley Park Hospital (GB), East Surrey Hospital (GB), Croydon University Hospital (GB), Epsom and St Helier University Hospitals NHS Trust (GB), East Kent Hospitals University NHS Foundation Trust (GB), Turks and Caicos National Museum (TC), St Peter's Hospital (GB), National University Hospital of Iceland (IS), Royal Marsden Hospital (GB), Kingston Hospital (GB), Royal Surrey NHS Foundation Trust (GB), University Hospitals Sussex NHS Foundation Trust (GB), University of Turin (IT), Newcastle University (GB)
Openalex Percentile: Top 56%
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.